Goldman Sachs Group Inc Blueprint Medicines Corp Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,046,535 shares of BPMC stock, worth $98.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,046,535
Previous 721,632 45.02%
Holding current value
$98.7 Million
Previous $66.7 Million 36.8%
% of portfolio
0.01%
Previous 0.01%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$82.48 - $101.39 $26.8 Million - $32.9 Million
324,903 Added 45.02%
1,046,535 $91.3 Million
Q3 2024

Nov 14, 2024
SELL
$84.1 - $120.5 $1.48 Million - $2.12 Million
-17,606 Reduced 2.38%
721,632 $66.7 Million
Q2 2024

Aug 13, 2024
BUY
$85.18 - $108.78 $14.7 Million - $18.8 Million
172,584 Added 30.46%
739,238 $79.7 Million
Q1 2024

May 15, 2024
SELL
$73.17 - $99.79 $834,211 - $1.14 Million
-11,401 Reduced 1.97%
566,654 $53.8 Million
Q4 2023

Feb 13, 2024
BUY
$43.96 - $92.84 $10.3 Million - $21.7 Million
233,337 Added 67.69%
578,055 $53.3 Million
Q3 2023

May 14, 2024
SELL
$46.9 - $66.0 $10.9 Million - $15.4 Million
-233,337 Reduced 40.37%
344,718 $17.3 Million
Q3 2023

Nov 14, 2023
SELL
$46.9 - $66.0 $2.09 Million - $2.95 Million
-44,638 Reduced 11.46%
344,718 $17.3 Million
Q2 2023

May 14, 2024
BUY
$42.2 - $66.37 $2.31 Million - $3.63 Million
54,765 Added 16.37%
389,356 $24.6 Million
Q2 2023

Aug 14, 2023
BUY
$42.2 - $66.37 $2.31 Million - $3.63 Million
54,765 Added 16.37%
389,356 $24.6 Million
Q1 2023

May 14, 2024
BUY
$37.97 - $50.0 $657,982 - $866,450
17,329 Added 5.46%
334,591 $15.1 Million
Q1 2023

May 11, 2023
BUY
$37.97 - $50.0 $657,982 - $866,450
17,329 Added 5.46%
334,591 $15.1 Million
Q4 2022

May 14, 2024
SELL
$41.06 - $66.48 $217,125 - $351,546
-5,288 Reduced 1.64%
317,262 $13.9 Million
Q4 2022

Feb 13, 2023
SELL
$41.06 - $66.48 $217,125 - $351,546
-5,288 Reduced 1.64%
317,262 $13.9 Million
Q3 2022

May 14, 2024
BUY
$49.93 - $77.7 $3.22 Million - $5 Million
64,406 Added 24.95%
322,550 $21.3 Million
Q3 2022

Nov 10, 2022
BUY
$49.93 - $77.7 $3.22 Million - $5 Million
64,406 Added 24.95%
322,550 $21.3 Million
Q2 2022

May 14, 2024
SELL
$45.23 - $70.15 $14.5 Million - $22.4 Million
-319,911 Reduced 55.34%
258,144 $13 Million
Q2 2022

Aug 15, 2022
SELL
$45.23 - $70.15 $2.2 Million - $3.41 Million
-48,632 Reduced 15.85%
258,144 $13 Million
Q1 2022

May 16, 2022
SELL
$54.1 - $110.08 $5.07 Million - $10.3 Million
-93,695 Reduced 23.4%
306,776 $19.6 Million
Q4 2021

Feb 14, 2022
SELL
$94.25 - $115.99 $20 Million - $24.7 Million
-212,594 Reduced 34.68%
400,471 $42.9 Million
Q3 2021

Nov 10, 2021
BUY
$80.98 - $109.47 $49.6 Million - $67.1 Million
613,065 New
613,065 $63 Million

Others Institutions Holding BPMC

# of Institutions
380
Shares Held
65.9M
Call Options Held
1.6M
Put Options Held
1.41M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.63B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email